Research map: Originator versus biosimilar adalimumab in hidradenitis suppurativa: a real-world cohort study

Back to the article

Papers in this map

  1. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa · Christos C. Zouboulis · 2015 · 1096 citations · Cited by this paper
  2. Aflibercept-ayyh (aflibercept 2 mg biosimilar) for treatment-naïve retinal vascular diseases: early real-world experience – the APEX study · 2026 · Related
  3. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa · Alexa B. Kimball · 2016 · 804 citations · Cited by this paper
  4. Efficacy of intravenous infliximab in axial spondyloarthritis: impact on disease activity, quality of life, and productivity in subgroups with psoriasis and inflammatory bowel disease · 2026 · Related
  5. Development and validation of the International Hidradenitis Suppurativa Severity Score System ( IHS 4), a novel dynamic scoring system to assess HS severity · Christos C. Zouboulis · 2017 · 481 citations · Cited by this paper
  6. Twelve-month changes in lipid-derived cardiovascular risk indices among patients with psoriasis receiving biologic therapy: a multicenter real-world retrospective cohort study · 2026 · Related
  7. Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa · Alexa B. Kimball · 2012 · 424 citations · Cited by this paper
  8. Anakinra treatment practices in colchicine-resistant familial Mediterranean fever: a survey of pediatric rheumatologists conducted through the PReS AID-WP and the Turkish pediatric rheumatology associations · 2026 · Related
  9. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group · Christos C. Zouboulis · 2018 · 257 citations · Cited by this paper
  10. Immunotherapy for patients with melanoma in East Asia: current evidence, future directions, and clinical implications · 2026 · Related
  11. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment · Alexa B. Kimball · 2014 · 211 citations · Cited by this paper
  12. Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials · 2026 · Related
  13. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study · Christos C. Zouboulis · 2018 · 193 citations · Cited by this paper
  14. The role of monoclonal antibodies in the treatment of lupus nephritis · 2026 · Related
  15. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study · Stanley B. Cohen · 2017 · 188 citations · Cited by this paper
  16. Identification of plaque psoriasis subgroups based on peripheral blood immune cells subtypes and their relationship with biologic therapy efficacy: a single-center longitudinal cohort study in China · 2026 · Related
  17. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches · Andrew Blauvelt · 2018 · 153 citations · Cited by this paper
  18. Biosimilars as antivirals: scientific and regulatory readiness for rapid, cost-effective deployment in infectious threats · 2026 · Related
  19. Inter‐rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa · Linnea Thorlacius · 2019 · 75 citations · Cited by this paper
  20. Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma · 2026 · Related
  21. Development and validation of IHS4 ‐55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa · Thrasyvoulos Tzellos · 2022 · 66 citations · Cited by this paper
  22. Real‐world effectiveness of adalimumab in patients with moderate‐to‐severe hidradenitis suppurativa: the 1‐year SOLACE study · Wayne P. F. Gulliver · 2021 · 29 citations · Cited by this paper
  23. Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa · Trinidad Montero‐Vílchez · 2022 · 28 citations · Cited by this paper
  24. The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study · Hans Christian Ring · 2022 · 26 citations · Cited by this paper
  25. Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study · Martina Burlando · 2022 · 25 citations · Cited by this paper
  26. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness? · Gabriele Roccuzzo · 2022 · 24 citations · Cited by this paper
  27. Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa · Federica Ricceri · 2020 · 22 citations · Cited by this paper
  28. Adalimumab and the Challenges for Biosimilars · Walid F. Gellad · 2019 · 17 citations · Cited by this paper
  29. Effectiveness of Biologic Therapy in Hidradenitis Suppurativa: Real‐World Clinical Outcomes and Lipid Profile Evaluation · Ruggero Cascio Ingurgio · 2025 · 16 citations · Cited by this paper
  30. Drug survival of adalimumab biosimilar vs adalimumab originator in hidradenitis suppurativa: Can equivalence be assumed? A retrospective cohort study · Mercè Grau‐Pérez · 2022 · 14 citations · Cited by this paper
  31. The Efficacy and Safety of Biosimilars in Hidradenitis Suppurativa: A Comprehensive Review · Eman Almukhadeb · 2024 · 5 citations · Cited by this paper
  32. Originator versus biosimilar adalimumab in hidradenitis suppurativa: A multicenter real-world analysis of clinical response, maintenance of response, and switching · Marra Jai Aghajani · 2025 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)